NICE and its value judgments: Authors' replyBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7468.741 (Published 23 September 2004) Cite this as: BMJ 2004;329:741
- Michael Rawlins, chairman (firstname.lastname@example.org),
- Tony Culyer, chief scientist
- National Institute for Clinical Excellence, London WC1V 6NA
- Institute for Work and Health, Toronto, Canada
EDITOR—Caan may be right about second line treatments, but the point applies to more than just paediatric prescribing. Fortunately, there is nothing in NICE's current appraisal methods to exclude these considerations,1 and we have already done so on several occasions.
House and Peters are wrong to call NICE's values utilitarian, but they are certainly consequentialist. By …